Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?

Documents similaires

• Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist
  par: Luděk Horváth, et autres
  Publié: (2025)
• Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
  par: Paschalis Karakasis, et autres
  Publié: (2024)
• Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
  par: Irl B. Hirsch, et autres
  Publié: (2024)
• Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
  par: Julio Rosenstock, et autres
  Publié: (2025)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  par: David C. Klonoff, et autres
  Publié: (2024)